Eosinophilic esophagitis (EoE) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Eosinophilic esophagitis (EoE)

Eosinophilic esophagitis (EoE) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

According to Thelansis it is estimated that approximately 55 patients per 100,000 people in the United States have EoE. According to Thelansis disease modeling data 66% of the patient population of total diagnosed patients in EU 5 markets belong to the adult (>18 years) with ~125,556 patients in year 2020,

Competitive landscape of Eosinophilic esophagitis (EoE) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Eosinophilic esophagitis (EoE) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Eosinophilic esophagitis (EoE) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Eosinophilic esophagitis (EoE) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Stage

1        Dupilumab        Regeneron Pharmaceuticals                Phase 3

2        Reslizumab        Ception Therapeutics                Phase 3

3        lirentelimab (AK002)        Allakos, Inc.                Phase 3

4        EUR-1100        Allergan    Phase 2

5        Benralizumab        AstraZeneca                Phase 3

6        APT-1011        Adare Pharmaceuticals, Inc. Phase 3

7        Florence        EMS                Phase 2

8        Budesonide        Shire                Phase 2

9        QAX576        Novartis Pharmaceuticals                Phase 2

10        Budesonide        Dr. Falk Pharma GmbH  Phase 3

11        RPC4046        Celgene                Phase 2

12        OC000459        Oxagen Ltd                Phase 2

13        CALY-002        Calypso Biotech BV  Phase 1

14        Omalizumab        Amerimmune Clinic (O & O Alpan LLC)                Phase 1

15        Montelukast/ Singulair        Mayo Clinic        Phase 1

16        Budesonide plus Prevacid        Meritage Pharma, Inc. Phase 2

17        Viaskin Milk 500 mcg        DBV Technologies Phase 2

18        Mepolizumab        GlaxoSmithKline                Phase 2